Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Ascendis Pharma A (ASND) over the last 14 years, with Q4 2025 value amounting to $5.8 million.

  • Ascendis Pharma A's Current Deferred Revenue rose 54996.61% to $5.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $5.8 million, marking a year-over-year increase of 54996.61%. This contributed to the annual value of $5.6 million for FY2025, which is 53680.62% up from last year.
  • Ascendis Pharma A's Current Deferred Revenue amounted to $5.8 million in Q4 2025, which was up 54996.61% from -$1.3 million recorded in Q4 2024.
  • Ascendis Pharma A's Current Deferred Revenue's 5-year high stood at $10.8 million during Q3 2022, with a 5-year trough of -$10.1 million in Q3 2023.
  • Its 5-year average for Current Deferred Revenue is -$337472.6, with a median of -$600726.1 in 2024.
  • Examining YoY changes over the last 5 years, Ascendis Pharma A's Current Deferred Revenue showed a top increase of 290472.05% in 2022 and a maximum decrease of 189576.43% in 2022.
  • Quarter analysis of 5 years shows Ascendis Pharma A's Current Deferred Revenue stood at $6.0 million in 2021, then skyrocketed by 48.26% to $8.8 million in 2022, then plummeted by 186.34% to -$7.6 million in 2023, then skyrocketed by 83.21% to -$1.3 million in 2024, then surged by 549.97% to $5.8 million in 2025.
  • Its last three reported values are $5.8 million in Q4 2025, -$1.3 million for Q4 2024, and -$600726.1 during Q3 2024.